Stream VByte: Faster Byte-Oriented Integer Compression

Arrays of integers are often compressed in search engines. Though there are many ways to compress integers, we are interested in the popular byte-oriented integer compression techniques (e.g., VByte or Google's Varint-GB). They are appealing due to their simplicity and engineering convenience. Amazon's varint-G8IU is one of the fastest byte-oriented compression technique published so far. It makes judicious use of the powerful single-instruction-multiple-data (SIMD) instructions available in commodity processors. To surpass varint-G8IU, we present Stream VByte, a novel byte-oriented compression technique that separates the control stream from the encoded data. Like varint-G8IU, Stream VByte is well suited for SIMD instructions. We show that Stream VByte decoding can be up to twice as fast as varint-G8IU decoding over real data sets. In this sense, Stream VByte establishes new speed records for byte-oriented integer compression, at times exceeding the speed of the memcpy function. On a 3.4GHz Haswell processor, it decodes more than 4 billion differentially-coded integers per second from RAM to L1 cache

Faster population counts using AVX2 instructions

Counting the number of ones in a binary stream is a common operation in database, information-retrieval, cryptographic and machine-learning applications. Most processors have dedicated instructions to count the number of ones in a word (e.g., popcnt on x64 processors). Maybe surprisingly, we show that a vectorized approach using SIMD instructions can be twice as fast as using the dedicated instructions on recent Intel processors. The benefits can be even greater for applications such as similarity measures (e.g., the Jaccard index) that require additional Boolean operations. Our approach has been adopted by LLVM: it is used by its popular C compiler (Clang)

Centrifugal Compressors 201

Short CourseThis course supplements the Centrifugal Compressor 101 course by covering in greater detail four key areas related to compressors: aerodynamics, rotordynamics, performance and mechanical testing, and surge control. It is intended for those who attended the 101 course and wish to learn more about these topics. The course is also structured for those practicing rotating machinery engineers who have a basic understanding of the topics covered in CC101 but wish to further their understanding in these key areas

Centrifugal Compressors 201

Short CourseThis course supplements the Centrifugal Compressor 101 course by covering in greater detail four key areas related to compressors: aerodynamics, rotordynamics, performance and mechanical testing, and surge control. It is intended for those who attended the 101 course and wish to learn more about these topics. The course is also structured for those practicing rotating machinery engineers who have a basic understanding of the topics covered in CC101 but wish to further their understanding in these key areas

Centrifugal Compressors 201

Short CourseThis course supplements the Centrifugal Compressor 101 course by covering in greater detail four key areas related to centrifugal compressors as described below. It is intended for those who attended the 101 and wish to learn more about these topics. The course is also structured for those practicing rotating machinery engineers that have a basic understanding of the topics covered in Centrifugal Compressors 101 but wish to further their understanding in these key areas

Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial

Importance: Sepsis induces profound metabolic derangements, while exogenous levocarnitine mitigates metabolic dysfunction by enhancing glucose and lactate oxidation and increasing fatty acid shuttling. Previous trials in sepsis suggest beneficial effects of levocarnitine on patient-centered outcomes. Objectives: To test the hypothesis that levocarnitine reduces cumulative organ failure in patients with septic shock at 48 hours and, if present, to estimate the probability that the most efficacious dose will decrease 28-day mortality in a pivotal phase 3 clinical trial. Design, Setting, and Participants: Multicenter adaptive, randomized, blinded, dose-finding, phase 2 clinical trial (Rapid Administration of Carnitine in Sepsis [RACE]). The setting was 16 urban US medical centers. Participants were patients aged 18 years or older admitted from March 5, 2013, to February 5, 2018, with septic shock and moderate organ dysfunction. Interventions: Within 24 hours of identification, patients were assigned to 1 of the following 4 treatments: low (6 g), medium (12 g), or high (18 g) doses of levocarnitine or an equivalent volume of saline placebo administered as a 12-hour infusion. Main Outcomes and Measures: The primary outcome required, first, a greater than 90% posterior probability that the most promising levocarnitine dose decreases the Sequential Organ Failure Assessment (SOFA) score at 48 hours and, second (given having met the first condition), at least a 30% predictive probability of success in reducing 28-day mortality in a subsequent traditional superiority trial to test efficacy. Results: Of the 250 enrolled participants (mean [SD] age, 61.7 [14.8] years; 56.8% male), 35, 34, and 106 patients were adaptively randomized to the low, medium, and high levocarnitine doses, respectively, while 75 patients were randomized to placebo. In the intent-to-treat analysis, the fitted mean (SD) changes in the SOFA score for the low, medium, and high levocarnitine groups were -1.27 (0.49), -1.66 (0.38), and -1.97 (0.32), respectively, vs -1.63 (0.35) in the placebo group. The posterior probability that the 18-g dose is superior to placebo was 0.78, which did not meet the a priori threshold of 0.90. Mortality at 28 days was 45.9% (34 of 74) in the placebo group compared with 43.3% (45 of 104) for the most promising levocarnitine dose (18 g). Similar findings were noted in the per-protocol analysis. Conclusions and Relevance: In this dose-finding, phase 2 adaptive randomized trial, the most efficacious dose of levocarnitine (18 g) did not meaningfully reduce cumulative organ failure at 48 hours